Cisplatin-Based Combinations-Associated Vasculopathy - A Disproportionality Analysis of Real-World Pharmacovigilance Data

View Full Paper

Ask AI

Bookmark

Cisplatin-based combinations significantly increased reports of vasculopathy, indicating potential safety concerns for these treatments.
Between 2016 and 2020, over 23,000 adverse events were reported for cisplatin combinations, against nearly 7 million in non-cases.
Disproportionality analysis using Reporting Odds Ratio identified significant risk signals for vascular adverse events among four therapy groups.
Effective monitoring of thrombotic events related to cisplatin-based chemotherapy is essential for patient safety and management strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Disproportionality analysis highlights increased vascular risks in patients using cisplatin-based combinations, stressing the need for monitoring.

Pandya et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Disproportionality analysis highlights increased vascular risks in patients using cisplatin-based combinations, stressing the need for monitoring.